胰腺癌（PC）是死亡率最高的癌症之一，五年生存率仅为7％。在诊断时，仅有20％的患者的PC仅限于胰腺内，而在50％的患者中已经发生了转移。这是由于它的晚期诊断，使得放射疗法等治疗变得困难，降低了生存率。因此，本研究的重要性在于检测可能成为这种肿瘤的生物标志物的基因，特别是与人类秘沃相对应的基因。这些基因参与了负责肿瘤迁移和对治疗的抵抗的通路，以及其他重要因素。为了实现这些目标，采用了以下在线工具和平台来发现和验证这些生物标志物：人类蛋白质图谱数据库、Xena浏览器平台、基因表达数据库、EnrichR平台和Kaplan-Meier绘图平台。我们的研究采用了一种方法，可以识别与PC放射治疗效果相关的潜在生物标志物。炎症通路主要得到了丰富，与生物过程调控相关，主要涉及细胞因子衍生蛋白质，这些蛋白质负责肿瘤进展和其他有助于疾病发展的过程。与其他治疗形式结合使用时，放射疗法治疗显示出更大的疗效，因为它减少了与肿瘤进展相关的重要基因的表达。版权所有 © 2023，国际抗癌研究学院（George J. Delinasios博士），保留所有权利。

Pancreatic cancer (PC) has one of the highest mortality rates, with an overall five-year survival rate of only 7%. When diagnosed, PC is limited to the pancreas in only 20% of patients, whereas in 50% it has already metastasized. This is due to its late diagnosis, which makes the treatments used, such as radiotherapy, difficult, and reduces survival rates. Therefore, the importance of this study in detecting genes that may become possible biomarkers for this type of tumor, especially regarding the human secretome, is highlighted. These genes participate in pathways that are responsible for tumor migration and resistance to therapies, along with other important factors.To achieve these goals, the following online tools and platforms have been expanded to discover and validate these biomarkers: The Human Protein Atlas database, the Xena Browser platform, Gene Expression Omnibus, the EnrichR platform and the Kaplan-Meier Plotter platform.Our study adopted a methodology that allows the identification of potential biomarkers related to the effectiveness of radiotherapy in PC. Inflammatory pathways were predominantly enriched, related to the regulation of biological processes, primarily in cytokine-derived proteins, which are responsible for tumor progression and other processes that contribute to the development of the disease.Radiotherapy treatment demonstrated greater efficacy when used in conjunction with other forms of therapy since it decreased the expression of essential genes involved in several inflammatory pathways linked to tumor progression.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.